StreetAlpha.app
Home › Stocks › NERV

Minerva Neurosciences, Inc. (NERV)

$2.16
▼ −1.82%
LAST CLOSE · NOV 17

Minerva Neurosciences is a Burlington, Massachusetts drug developer working on roluperidone, a candidate for schizophrenia. It last closed at $2.16 on Nov 17, down 1.82% on the day.

AI Auto Pilots
Is NERV in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$290.9M
Valuation
Market cap
$107.6M
49.8M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$20.2M
At Sep 30
Shareholder equity
−$97.5M
Shares outstanding
49.8M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$49.9M−$49.9MFY2021FY2022: −$32.1M−$32.1MFY2022FY2023: −$30.0M−$30.0MFY2023FY2024: $1.4M$1.4MFY2024FY2025: −$293.4M−$293.4MFY2025

From NERV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Last report
Nov 6
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated NERV in the past 90 days.
Average 12-month target
No price targets on NERV in the past 90 days.
Latest rating changes
JefferiesUpgrade
Aug 14Buy$10
CitizensInitiated
Apr 15Buy$14
DateFirmActionRatingPrice target
Aug 14JefferiesUpgradeBuy$10
Apr 15CitizensInitiatedBuy$14
Loading…

Technical Analysis

NERV · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 9% below its 20 day and 35% below its 50 day average. It is 122% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $2.04, and the nearest resistance the Pivot R1 at $2.29.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 11.1%/day
Key levels
$8.8052 week high+307.4%
$4.79200 day average+121.8%
$3.73100 day average+72.7%
$2.9250 day average+35.2%
$2.65Swing high (Oct 23)+22.7%
$2.3520 day average+8.8%
$2.29Pivot R1+6.0%
$2.16Pivot+0.0%
$2.16Last close
$2.04Pivot S1−5.6%
$1.9652 week low−9.3%
$1.96Swing low (Oct 30)−9.3%
Indicators
RSI (14)36.83Weak, oversold below 30Neutral
MACD-0.17Above its signal lineBullish
Stochastic32.5Middle of its rangeNeutral
ADX (14)20.3Weak trend
Williams %R-75.0Oversold below −80, overbought above −20Neutral
CCI (20)-131.8Oversold below −100, overbought above 100Oversold
Rate of change−8.1%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 11.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NERV

What happened before

See how NERV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NERV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NERV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NERV in the last 90 days.

Loading…

See today’s whale options flow across the market →

NERV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲33 buying vs 11 selling
  • ▲Held by funds +1.7 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6558+12.1%
In funds' top 10110.0%
Held by funds86.6%84.9%+1.7 pts
New / increased9 / 2422 / 15−10.8%
Reduced / sold out9 / 27 / 9−31.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NERV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NERV is in one of them and how their past NERV trades turned out.

NERV in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NERV in an article yet. Here's the latest on the wider market.

About Minerva Neurosciences

Minerva Neurosciences is a pharmaceutical company based in Burlington, Massachusetts. Its main focus is roluperidone, a drug candidate being developed to treat negative symptoms of schizophrenia. The candidate is still moving through clinical trials and the U.S. regulatory approval process, so it is not yet approved for sale. The company's intended customers are patients with schizophrenia, along with the doctors and healthcare providers who treat them.

Headquarters
Burlington, MA
Founded
2007